Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

48

Revenue 2017

Crestor

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Crestor was produced by AstraZeneca and Shionogi.

Crestor can't top Lipitor in head-to-head study

A study comparing the effects of AstraZeneca's Crestor (rosuvastatin calcium) with Pfizer's Lipitor (atorvastatin calcium) in has found no difference between the statin drugs in preventing the progression of ... These results are good news for patients

AZ's Q3 income up as sales stay flat

The company said more than $350m of revenue was lost due to generic competition, cancelling out strong performances for statin Crestor (rosuvastatin calcium), antipsychotic Seroquel XR (quetiapine fumarate) and Symbicort

Crestor fails to outshine Lipitor

AstraZeneca's cholesterol drug Crestor has failed to show an advantage over its rival Lipitor in study data released by the pharmaceutical company. ... AstraZeneca's (AZ) cholesterol drug Crestor (rosuvastatin) has failed to show an advantage over its

FDA panel wants new Trilipix data

blockbuster statin Crestor (rosuvastatin), for the treatment of mixed dyslipidaemia.

AstraZeneca partners with cooking website

AstraZeneca has entered into a partnership with Food University, a web-based culinary platform, to discuss healthy eating in support of the company's cholesterol drug Crestor. ... Crestor, a "super-statin" launched in 2003, has been one of AstraZeneca's

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...